AI assistant
Sending…
AIM ImmunoTech Inc. — Director's Dealing 2017
Aug 16, 2017
35334_dirs_2017-08-16_cfc80946-232c-4aa7-8faa-83deae3470ee.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2017-08-15
Reporting Person: MITCHELL WILLIAM M (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-08-15 | Options to buy Common Stock | $0.41 | A | 25953 | Acquired | 2027-08-15 | Common Stock (25953) | Direct |
Footnotes
F1: This option is being issued in exchange for a voluntary 100% reduction in Director's fees.